Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Reports from University of Oviedo describe recent advances in bladder cancer
June 30th, 2009
In this recently published study, investigators in Oviedo, Spain conducted a study "To evaluate the prognostic factors of recurrence and progression after intravesical adjuvant bacillus Calmette-Guerin (BCG) immunotherapy in patients with non-muscle-invasive bladder tumors. From February 1990 to May 1999, the Spanish Club Urologico Espanol de Tratamiento Oncologico (CUETO) group has performed four randomized phase 3 studies comparing different intravesical treatments in patients with noninvasive bladder cancer." "Data from 1062 evaluable patients treated only with BCG were analyzed. Most patients received BCG once weekly for 6 consecutive weeks and a short-term BCG...
Source: Cancer Weekly (2009-06-30)
|
